Hypocalcemia and parathyroid function in metastatic prostate cancer

Endocrine Practice

Volumn 11, Issue 4, 2005, Pages 254-258

  Tandon, Prabhat K ^a   Rizvi, Ali A ^a  

^a UNIVERSITY OF SOUTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PARATHYROID HORMONE;

AGED; ARTICLE; BLOOD; BONE TUMOR; CASE REPORT; HUMAN; HYPOCALCEMIA; MALE; METASTASIS; PARATHYROID GLAND; PATHOLOGY; PATHOPHYSIOLOGY; PROSTATE TUMOR;

AGED, 80 AND OVER; BONE NEOPLASMS; HUMANS; HYPOCALCEMIA; MALE; PARATHYROID GLANDS; PARATHYROID HORMONE; PROSTATIC NEOPLASMS;

EID: 33644671769     PISSN: 1530891X     EISSN: None     Source Type: Journal    
DOI: 10.4158/EP.11.4.254     Document Type: Article

References (32)

1. Chu KC, Tarone RE, Freeman HP. Trends in prostate cancer mortality among black men and white men in the United States. Cancer. 2003;97:1507-1516.
2. Goltzman D. Mechanisms of the development of osteoblastic metastases. Cancer. 1997;80(8 Suppl):1581-1587.
3. Urwin GH, Percival RC, Harris S, Beneton MN, Williams JL, Kanis JA. Generalised increase in bone resorption in carcinoma of the prostate. Br J Urol. 1985;57:721-723.
4. Rico H, Uson A, Hernandez ER, Prados P, Paramo P, Cabrenes JA. Hyperparathyroidism in metastases of prostate carcinoma: a biochemical, hormonal, and histomorphometric study. Eur Urol. 1990;17:35-39.
5. Galasko CS. Mechanisms of bone destruction in the development of skeletal metastases. Nature. 1976;263:507-508.
6. Coleman RE. Skeletal complications of malignancy. Cancer. 1997;80(8 Suppl):1588-1594.
7. Stetler-Stevenson WG, Aznavoorian S, Liotta LA. Tumor cell interactions with the extracellular matrix during invasion and metastasis. Annu Rev Cell Biol. 1993;9:541-573.
8. Yoneda T. Cellular and molecular mechanisms of breast and prostate cancer metastasis to bone. Eur J Cancer. 1998;34:240-245.
9. van Dijk JM. Hypercalcemia in prostatic carcinoma: case report and review of the literature. Am J Clin Oncol. 1993;16:329-331.
10. Mahadevia PS, Ramaswamy A, Greenwald ES, Wollner DI, Markham D. Hypercalcemia in prostatic carcinoma: report of eight cases. Arch Intern Med. 1983;143:1339-1342.
11. George AL Jr, Remler RB, Heim CR, Warner JJ. Hypercalcemia in carcinoma of the prostate: case report and review of the literature. J Urol. 1987;137:309-311.
12. Smith DC, Tucker JA, Trump DL. Hypercalcemia and neuroendocrine carcinoma of the prostate: a report of three cases and a review of the literature. J Clin Oncol. 1992;10: 499-505.
13. Lim SC, Tan CE, Aw TC, et al. A man with osteoblastic metastasis and hypocalcaemia. Singapore Med J. 2000;41:74-76.
14. Szentirmai M, Constantinou C, Rainey JM, Loewenstein JE. Hypocalcemia due to avid calcium uptake by osteoblastic metastases of prostate cancer. West J Med. 1995;163:577-578.
15. Riancho JA, Arjona R, Valle R, Sanz J, Gonzalez-Macias J. The clinical spectrum of hypocalcaemia associated with bone metastases. J Intern Med. 1989;226: 449-452.
16. Raskin P, McClain CJ, Medsger TA Jr. Hypocalcemia associated with metastatic bone disease: a retrospective study. Arch Intern Med. 1973;132:539-543.
17. Ludwig GD. Hypocalcemia and hypophosphatemia accompanying osteoblastic osseous metastases: studies of calcium and phosphate metabolism and parathyroid function. Ann Intern Med. 1962;56:676-677.
18. Charhon SA, Chapuy MC, Delvin EE, Meunier PJ. Parathyroid function and vitamin D status in patients with bone metastases of prostatic origin. Miner Electrolyte Metab. 1985;11:117-122.
19. Minisola S, Perugia G, Scarda A, et al. Biochemical picture accompanying sclerotic bone metastases of prostatic origin. Br J Urol. 1987;60:443-446.
20. Murray RM, Grill V, Crinis N, Ho PW, Davison J, Pitt P. Hypocalcemic and normocalcemic hyperparathyroidism in patients with advanced prostatic cancer. J Clin Endocrinol Metab. 2001;86:4133-4138.
21. Li Y, Song YH, Rais N, et al. Autoantibodies to the extracellular domain of the calcium sensing receptor in patients with acquired hypoparathyroidism. J Clin Invest. 1996;97: 910-914.
22. Kukreja SC, Shanmugam A, Lad TE. Hypocalcemia in patients with prostate cancer. Calcif Tissue Int. 1988;43: 340-345.
23. Tommaso CL, Tucci JR. Metabolic studies in a case of hypocalcemia and osteoblastic metastases. Arch Intern Med. 1979;139:238-241.
24. Smallridge RC, Wray HL, Schaaf M. Hypocalcemia with osteoblastic metastases in patient with prostatic carcinoma: a cause of secondary hyperparathyroidism. Am J Med. 1981;71:184-188.
25. Lyles KW, Berry WR, Haussler M, Harrelson JM, Drezner MK. Hypophosphatemic osteomalacia: association with prostatic carcinoma. Ann Intern Med. 1980; 93:275-278.
26. Nakahama H, Nakanishi T, Uno H, et al. Prostate cancer-induced oncogenic hypophosphatemic osteomalacia. Urol Int. 1995;55:38-40.
27. Blutt SE, Weigel NL. Vitamin D and prostate cancer. Proc Soc Exp Biol Med. 1999;221:89-98.
28. Chen TC, Holick MF, Lokeshwar BL, Burnstein KL, Schwartz GG. Evaluation of vitamin D analogs as therapeutic agents for prostate cancer. Recent Results Cancer Res. 2003;164:273-288.
29. Johnson CS, Hershberger PA, Bernardi RJ, Mcguire TF, Trump DL. Vitamin D receptor: a potential target for intervention. Urology. 2002;60(3 Suppl 1):123-130.
30. Johnson CS, Hershberger PA, Trump DL. Vitamin Drelated therapies in prostate cancer. Cancer Metastasis Rev. 2002;21:147-158.
31. Papapoulos SE, Hamdy NA, van der Pluijm G. Bisphosphonates in the management of prostate carcinoma metastatic to the skeleton. Cancer. 2000;88(12 Suppl): 3047-3053.
32. Dawson NA. Therapeutic benefit of bisphosphonates in the management of prostate cancer-related bone disease. Expert Opin Pharmacother. 2003;4:705-716.